ASX ANNOUNCEMENT 11 September 2017

H.C. Wainwright & Co. Updates Cynata Research Coverage Melbourne, Australia; 11 September, 2017: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), announced today that H.C. Wainwright & Co., LLC, a leading US-based investment bank, has published updated equity analyst coverage with a target price revision.

The full report can be viewed on Cynata's website at www.cynata.com .

Ends

CONTACTS: Dr Ross Macdonald, CEO, 0412 119343, ross.macdonald@cynata.com

Daniel Paproth, Australia Media Contact, 0421 858 982 , daniel.paproth@mcpartners.com.au Laura Bagby, U.S. Media Contact, 312-448-8098, lbagby@6degreespr.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company developing therapies based on its proprietary Cymerus™ stem cell technology platform. Cymerus overcomes critical issues in the production of therapeutic mesenchymal stem cells (MSCs) by enabling the economical manufacture of commercial-scale MSCs, independent of multi-donor limitations. Cymerus' novel approach utilises induced pluripotent stem cells (iPSCs) derived from a single blood donation to generate mesenchymoangioblasts (MCAs), a precursor that is used to manufacture an unlimited number of therapeutic MSCs. Cynata's unique "off-the-shelf" Cymerus platform has the potential to create a new standard in the development and manufacture of stem cell therapeutics.

Cynata Therapeutics Limited

Level 3, 62 Lygon Street, Carlton, Victoria 3053, Australia PO Box 7165, Hawthorn North, Victoria 3122

T: + 613 9824 5254 F: + 613 9822 7735 E: admin@cynata.com ABN - 98 104 037 372

Cynata Therapeutics Ltd. published this content on 11 September 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 10 September 2017 22:48:03 UTC.

Original documenthttp://cynata.com/wp-content/uploads/2017/09/17.09.11.HC-Wainwrigh-^0-Co-Updates-CYP-Research-Coverage.pdf

Public permalinkhttp://www.publicnow.com/view/0AB936719F4939FF20088E893103B28BA3861B6D